Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.42 |
| ▸ | HRH1 | P35367 | 9/20 | 0.42 |
| ▸ | HRH2 | P25021 | 8/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034791 | 0.83 | KDM4E (0.47) | MEN1KMT2A | |
| SCHEMBL7035436 | 0.81 | MEN1 (0.40) | KCNA5MEN1KMT2AHRH3HRH1 | |
| SCHEMBL7035876 | 0.81 | MEN1 (0.36) | KCNA5MEN1KMT2AHRH3HRH1 | |
| SCHEMBL7034768 | 0.78 | MKNK1 (0.46) | HRH1HRH2 | |
| SCHEMBL7030745 | 0.76 | SIGMAR1 (0.56) | HRH3HRH1HRH2 | |
| SCHEMBL7033716 | 0.76 | KCNH2 (0.39) | KCNA5MEN1KMT2A | |
| SCHEMBL7089730 | 0.76 | KCNA5 (0.36) | KCNA5MEN1KMT2A | |
| SCHEMBL6996340 | 0.74 | S1PR5 (0.45) | HRH3HRH1HRH2LTA4H | |
| SCHEMBL7035866 | 0.74 | HRH3 (0.49) | KCNA5HRH3HRH1HRH2 | |
| SCHEMBL7031866 | 0.73 | HRH3 (0.45) | KCNA5HRH3HRH1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | KCNA5 79/4885MEN1 2260/4885KMT2A 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.